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Abstract
Infections of the female reproductive tract are a major cause of morbidity and mortality in humans, requiring significant
investment to sustain treatment and representing a major challenge to health. The increasing prevalence of bacterial resistance,
and an almost complete absence of new antibiotic therapies for the past five decades, mean there is a desperate need for novel
approaches to the treatment of bacterial infections. Within the present study, we demonstrate the effective ex vivo treatment of
bacterial infection of the female reproductive tract using a controlled-release, liquid crystal-based platform. Liquid crystal
encapsulation of ciprofloxacin significantly enhanced its bactericidal efficacy and reduced cell toxicity. Liquid crystal structures
are low-cost, simple to manufacture and provide a sustained-release profile of encapsulated ciprofloxacin. Treatment of
Escherichia coli infected reproductive tract epithelial cells and whole organ cultures with liquid crystal encapsulated ciproflox-
acin proved to be an effective strategy for reducing bacterial load and reproductive tract inflammatory responses to infection.
These data suggest that such an approach could provide an efficacious treatment modality for enhancing the effectiveness of
current antibiotic therapies.
Keywords Liquid crystal . Drug delivery . Female reproductive tract . Bacterial infection . Female reproductive tract infection .
Ciprofloxacin
1 Introduction
Sexually transmitted infections and their associated diseases
represent one of the main challenges in worldwide
reproductive health (Horne et al. 2008). Despite sustained
activity aimed at preventing such infections, they remain a
significant socio-economic burden with the most prevalent
causative agents being Herpes simplex virus type 2, group B
streptococcus, Treponema pallidum (syphilis), bacterial vagi-
nosis, Hepatitis B virus (hepatitis), Neisseria gonorrhoeae
(gonorrhea), Chlamydia trachomatis, and human immunode-
ficiency viruses (HIVs) (Wira et al. 2011). According toWorld
Health Organization (WHO) estimates, in 2008 there were
more than 498 million new cases of over 30 different sexually
transmitted infections. These included infection with
Trichomonas vaginalis (276 million new cases), Chlamydia
trachomatis (106million new cases), Treponema pallidum (10
million new cases), HIV (2.7 million new cases) andNeisseria
gonorrhoeae (106 million new cases) (WHO 2012).
The female reproductive tract has an abundant natural bac-
terial flora, dominated in most women by Lactobacillus spe-
cies, which represent 90–95% of the total bacteria in the re-
productive tract (Delaney and Onderdonk 2001; Larsen and
Monif 2001; Srinivasan et al. 2010). Lactobacillus-dominance
is not universal however, with several studies showing the
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presence of a diverse, heterogeneous microbiota that extends
throughout the reproductive tract in women without reproduc-
tive tract disease (Chen et al. 2017; Lambert et al. 2013; Ravel
et al. 2013; Srinivasan et al. 2010). Lactobacillus species also
do not dominate throughout a woman’s lifetime, with anaer-
obes and Escherichia coli most abundant during childhood
and after menopause, when lower estrogen levels reduce the
abundance of glycogen in the vaginal epithelium, which is
essential for Lactobacillus growth and colonization
(Brotman et al. 2014; Galhardo et al. 2006; Hillier and Lau
1997). The presence of Lactobacillus species is currently ac-
cepted as a biomarker of healthy status (Amabebe and
Anumba 2018; das Neves et al. 2014). Through the production
of lactic acid, which lowers vaginal pH, together with the pro-
duction of hydrogen peroxide, bacteriocins and other antimi-
crobial compounds, Lactobacilli help to maintain vaginal ho-
meostasis by creating an environment unsuitable for neutro-
philic bacteria and by competing for nutrients, which deters the
growth of pathogenic bacteria (Barbés and Boris 1999;
Eschenbach et al. 1989; Tachedjian et al. 2018). Indeed, mod-
ification of these physiological conditions to a pH above 4.5
increases the risk of other bacterial infections including sexu-
ally transmitted infections and those associated with bacterial
vaginosis (Aldunate et al. 2015; Daniel Johannes Rönnqvist
et al. 2006;Mastromarino et al. 2014;McLaughlin et al. 2018).
Early and effective treatment of reproductive tract infections
is essential to limit transmission of disease and to reduce and/or
prevent associated morbidities. The development of antibiotic
resistance by pathogens to many antibiotics has increased con-
cerns about the effective management of these diseases (Alirol
et al. 2017; Bala et al. 2007; P. Health England 2013; Laibl et al.
2005; Martin et al. 2006; McCarthy 2007; MMWR 2006; Nys
et al. 2004; Wang et al. 2005). For example, a positive correla-
tion between ciprofloxacin resistance and gonorrhea incident
rates has been reported in several countries leading to the drug
being removed as the primary treatment option (Bala et al.
2007; Chesson et al. 2014; McCarthy 2007; MMWR 2006).
Therefore, finding a way to optimally identify patients more
likely to respond positively to an antibiotic regimen can repre-
sent a competitive advantage for diseasemanagement.With this
in mind, the UCLAHealth Group introduced a genotypic assay
to predict the susceptibility of N. gonorrhoea to ciprofloxacin,
thus repositioning this drug as a valuable tool if the correct
patient cohort is identified (Allan-Blitz et al. 2016). The same
approach is true for other bacterial infections. In addition, a
drive to reduce the amount of administered drug, which favors
a more localized treatment approach, would reduce negative
side effects such as diarrhea, nausea and vomiting, and possibly
delay the onset of drug resistance.
Localised treatments of reproductive tract infections are
favoured over oral approaches because they achieve higher
local drug concentrations and avoid affecting the gastrointes-
tinal tract microbiome (Alexander et al. 2004; Vermani and
Garg 2000). Several different delivery modalities are currently
marketed including tablets, capsules, pessaries and semisolids
(Henderson 1958; Das Neves and Bahia 2006; Pavelić et al.
2005; Slack and Nichols 1982; Yao et al. 2016), but most are
associated with poor distribution and retention due to the self-
cleaning action of the vagina (Hussain and Ahsan 2005). A
drive towards the use of semisolids (creams or gels), due to the
ease of application and the symptomatic relief provided by the
additional moisture provided, is evident (das Neves 2014;
Palmeira-de-Oliveira et al. 2015).
The need to improve drug delivery beyond the classical
pharmaceutical forms has driven the development of novel
delivery systems designed to improve patient compliance, en-
hance cellular targeting, extend drug release profiles and re-
duce harmful side-effects. Several of these new pharmaceuti-
cal compositions such as liposomes, polymeric systems or
cyclodextrins, are already marketed. Their advantage is to
offer improved therapeutic profiles by encapsulating a drug,
thereby protecting it from degradation, whilst also providing
the opportunity for the attachment of targeting molecules on
the outside of the carrier (Chen et al. 2014).
Liquid crystals are an emerging class of drug delivery sys-
tems made of polar lipids able to spontaneously reorganize
themselves into three-dimensional structures (namely liquid
crystalline phases) when in contact with water (Shah et al.
2001). They have a malleable structure, determined by the
local physico-chemical properties, meaning their structure
can be controlled to allow both ease of administration and
sustained drug release (Chaudhary et al. 2016). Liquid crystals
exhibit both optical and electrical anisotropy, as well as flow
properties and molecular mobility. Whilst in practice liquid
crystals do not transition directly from a liquid to a solid state,
under certain conditions they exhibit molecularly organised
intermediate phases (mesophases) with liquid and solid state
properties (Zabara and Mezzenga 2014). Liquid crystals that
form mesophases in appropriate solvents, named lyotropic
liquid crystals, are based on lipids that spontaneously self-
assemble in an aqueous environment. They are characterised
by nanostructured hydrophilic and hydrophobic domains sep-
arated by lipid bilayers, and form following exposure to a
polar (aqueous) environment (Zabara and Mezzenga 2012).
In the present study we evaluate controlled antibiotic deliv-
ery in cell and tissue models using ciprofloxacin, a second-
generation fluoroquinolone, with broad-spectrum antibiotic
activity against both Gram-positive and Gram-negative bacte-
ria (LeBel 1988; Wiseman and Balfour 1994) encapsulated in
liquid crystal. By demonstrating how liquid crystals can be
used as a drug delivery system in the treatment of bacterial
infections of the female reproductive tract, and that liquid
crystal formulations of ciprofloxacin significantly enhance
bacterial killing compared to the free drug formulation, we
pave the way for tailored, controlled-release treatments of
bacterial infections within the female reproductive tract.
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2 Methods and materials
2.1 Preparation of lamellar phase ciprofloxacin
emulsion (95% Monomuls® + 5% - 0.05% TFA)
A solution of 0.05% trifluoroacetic acid (TFA, Sigma-Aldrich,
Dorset, UK) was prepared in deionised water, and ciproflox-
acin (Sigma-Aldrich) was dissolved in it to the desired final
concentration. The monoemulsion solution was obtained by
adding 4.75 g of Monomuls® 90–018 (BASF, Cheadle, UK)
to a glass beaker and heating it to 40 °C in a water bath. Once
the monoemulsion becamemolten, 250μl of the ciprofloxacin
solution were added and the emulsion mixed. The ciproflox-
acin emulsion could be maintained in the lamellar phase at
37 °C until needed.
2.2 Preparation of cubic phase ciprofloxacin emulsion
(75% Monomuls® + 25% - 0.05% TFA)
A solution of 0.05% TFA was prepared in deionised water,
and ciprofloxacin was dissolved in it to the desired final con-
centration. The monoemulsion solution was obtained by
adding 3.25 g of Monomuls® 90–018 into a glass beaker
and heating it to 40 °C in a water bath. Once the
monoemulsion became molten, 1250 μl of the ciprofloxacin
solution was added andmixed with a glass wand. The solution
was cooled to ambient room temperature, undergoing a phase
shift to the cubic structure in the process, and stored at room
temperature until needed.
2.3 Characterization of liquid and cubic phases
by scanning electron microscopy
Analysis was performed as previously described (Tan et al.
2008). Briefly, samples were deposited on a silicon surface
and snap frozen in liquid nitrogen to ensure the conformation-
al stability of the liquid crystals. The product was then coated
with a 2 nm thick carbon coating and SEM images were ac-
quired using an S-4800 scanning electron microscope
(Hitachi) operated at accelerating voltages of 2 or 10 kV.
2.4 Drug release profiling by high-pressure liquid
chromatography (HPLC)
The release of ciprofloxacin from cubic phase ciprofloxacin
emulsion was measured using dialysis membrane and HPLC.
Cubic phase ciprofloxacin emulsion was placed into dialysis
tubing cellulose membrane (14,000 MWCO, Sigma-Aldrich,
UK) and each end of the tubing sealed. The sealed membrane
was then placed in a solution of 0.05%TFA in deionised water
and samples extracted at various time points over a 72-h peri-
od and stored at 4 °C ready for HPLC analysis. HPLC analysis
was performed as previously described by Locatelli and col-
leagues (Locatelli et al. 2015).
2.5 Primary cell and organ culture
Uteri with no gross evidence of reproductive disease or mi-
crobial infection, were collected from post-pubertal mixed-
breed beef cattle (n = 16 over a 3-month period) within
15 min of slaughter as part of the routine operation of a com-
mercial slaughterhouse. Postpartum cattle were not used be-
cause of the ubiquitous bacterial contamination and disruption
of the epithelium that is typical of the puerperal endometrium
(Herath et al. 2009;Wathes et al. 2009). The animals were 20–
26 months old, reared on extensive grassland and had never
been pregnant or inseminated. The stage of reproductive cycle
was determined by examination of ovarian morphology and
vasculature, as described previously, and animals on days 1 to
4 of the oestrus cycle were used because, similar to postpar-
tum cows, peripheral plasma ovarian hormone concentrations
are basal (Ireland et al. 1979). The uteri were kept on ice for
approximately 1 h until further processing at the laboratory.
External surfaces were washed with 70% ethanol and the uter-
ine horn opened longitudinally with sterile scissors. Since in-
nate immune responses are the same irrespective of the horn
used, one horn was used for the isolation of purified endome-
trial cell populations, and the contralateral horn used for organ
culture (Saut et al. 2014).
Endometrial cells were isolated as described previously
(Cronin et al. 2012; Herath et al. 2006). Epithelial and stromal
cell populations were distinguished by cell morphology, the
presence of cytokeratin and vimentin respectively, and the ab-
sence of immune cell contamination was confirmed by the ab-
sence of CD45, as described previously (Herath et al. 2006;
Turner et al. 2014). The epithelial and stromal cells were cul-
tured in 1 ml complete medium per well, comprising: Phenol-
red free Roswell ParkMemorial Institute (RPMI) 1640medium
(Sigma-Aldrich, Dorset, UK) containing 10% heat-inactivated
foetal bovine serum (FBS; Biosera, East Sussex, UK), and plat-
ed at 1 × 105 cells/ml in 24-well plates (TPP, Trasadingen,
Switzerland) ready for treatment. Ex vivo organ cultures
(EVOC) of the endometrium were collected using 8 mm diam-
eter punch biopsies as previously described (Borges et al.
2012). Tissues were cultured in 24-well plates (TPP) containing
2 ml complete medium per well, and treatments initiated within
4 h of slaughter. During treatment, cells or tissues were main-
tained in a humidified, 5% CO2 in air atmosphere incubator at
37 °C, with supernatants collected as indicated.
2.6 Immortalised cell-lines culture
The human HeLa cervical epithelial and human HEC1A en-
dometrial epithelial cell lines were obtained from the
European Collection of Cell Cultures (ECACC, Salisbury,
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UK) and cultured in Dulbecco’s Modified Eagle Medium/F-
12 nutrient mix (Thermofisher, Gloucester, UK) supplement-
ed with 10% foetal bovine serum (FBS). Sub-confluent cul-
tures were split using trypsin/ethylenediaminetetraacetic acid
(EDTA) and seeded into 24-well plates (TPP, Trasadingen,
Switzerland) in 1 ml of medium at 1 × 105 cells/ml for bacte-
rial infection experiments. Or were seeded onto 0.4 μm
collagen-coated Transwell™ support membranes (Sigma-
Aldrich, Dorset, UK) in 0.25 ml of medium at 1 × 105 cells/
ml for cell viability experiments.
2.7 Cell viability
Cell viability was assessed by the mitochondria-dependent
reduction of MTT to formazan, as described previously
(Mosmann 1983). The correlation between MTT OD570 mea-
surements and the number of live cells was confirmed using
trypan blue exclusion and counting the number of live cells
using a haemocytometer.
2.8 Bacterial culture
Cultures of E. coli (isolate MS499), collected from the uteri of
postpartum cows with persistent uterine disease, were grown
overnight in Luria-Bertani (LB) medium (Sigma-Aldrich) as
described previously (Amos et al. 2014; Sheldon et al. 2010).
The bacteria were diluted to 1 × 108 colony forming units
(CFU)/mL in medium and centrifuged at 1500×g for 10 min
at room temperature. The bacteria were then resuspended in
sterile PBS (Life Technologies Ltd., Paisley, UK) followed by
centrifugation at 6000×g for 10 min at 4 °C. After washing,
bacteria were diluted to 1 × 103 CFU/ml in LB medium for
bactericidal experiments, or complete cell culture medium for
cell/organ infection experiments. Where required, the number
of colony-forming units (CFU) was determined by plate
counts on LB agar plates following serial dilution of bacterial
cultures and/or cell/organ culture supernatants.
2.9 Enzyme-linked immuno sorbent assay (ELISA)
Concentrations IL-6 in cell and EVOC culture supernatants
were measured by ELISA according to the manufacturer’s
instructions Bovine IL-6 Screening Set ESS0029,
ThermoFisher Scientific). To account for differences between
the weights of EVOC tissues, concentrations are reported as
pg per mg tissue. The limit of detection for IL-6 was 35.6 pg/
ml; the intra-assay coefficient of variance was 1.2% and the
inter-assay coefficient of variance was 3.0%.
2.10 Statistical analysis
Statistical analyseswere performed using IBMSPSS Statistics
20. Initially the data were tested for homogeneity, and log or
square root transformed if appropriate. Data were analysed by
analysis of variance (ANOVA) using Dunnett’s pairwise mul-
tiple comparison t-test for individual group comparisons, or
by student’s t test. Data are presented as mean with standard
deviation (SD), P < 0.05 was considered statistically signifi-
cant, and n represents the number of independent experiments.
3 Results
3.1 The preparation of liquid crystal emulsions is
simple and reproducible
The preparation of different liquid crystal encapsulated cip-
rofloxacin emulsions was achieved by altering the propor-
tion of water used during synthesis (Fig. 1). Lamellar struc-
tures (Fig. 1a) were prepared using a lower proportion of
water (5% compared to 25% in cubic phase preparations)
and maintained in the lamellar phase by heating to 40 °C.
Cubic structures (Fig. 1b) were maintained at ambient room
temperature and readily phase shifted between a cubic and
lamellar structure by the application of heat (40 °C). For
both structures, ciprofloxacin was added whilst in the la-
mellar phase and becomes incorporated within the crystal
structure once it is heated to 40 °C. Drug equivalencies
were calculated based on the total amount of ciprofloxacin
added and the total volume of the emulsion whilst the liquid
crystal was in the lamellar phase.
A variety of techniques can be employed for liquid crystal
characterization, including small-angle x-ray scattering
(SAXS) (Freiberger and Glatter 2006; Goujon et al. 2015;
Mendez and Hammouda 2013) and Fourier Transform
Infrared Spectroscopy (FTIR) (Koenig et al. 1995; Pongali
Sathya Prabu et al. 2011), amongst others, and for an exhaus-
tive analysis of the different techniques used, the reader is
referred to the review by An and colleagues (An et al.
2016). In light of the previously published methodology we
used to prepare our liquid crystals, we chose scanning electron
microscopy (SEM) as a simple and robust approach to liquid
crystal characterization. Scanning electron microscopy
(Fig. 2) corroborated the findings of other groups working
with similar formulations (Nestor et al. 2013; Santamaría
et al. 2013). Images obtained at 60×, 110×, 350×, 799×,
800× and 2500× (Fig. 2a–f, respectively) show a crystalline
structure typical to cubic phase liquid crystal formulations.
3.2 Liquid crystal emulsions provide a sustained
release delivery modality
After fabrication and characterization of the liquid crystal
structures, the rate of release of encapsulated ciprofloxacin
was analysed using high pressure liquid chromatography
(HPLC). When plotted against a standard curve of
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ciprofloxacin release (Sup. Fig. 1), area under the curve
(AUC) analysis revealed a sustained release profile from cubic
phase liquid crystal, peaking at 4.07μg/ml after 72 h (Fig. 3),
confirming the suitability of this formulation for sustained,
slow-release treatment regimen.
3.3 Liquid crystal formulations have a limited impact
on epithelial cell viability
Before evaluating the efficacy of liquid crystal formulations
for the treatment of bacterial infections, we evaluated whether
there were any cytotoxic effects of the various formulations on
human cells (Fig. 4). HEC1A or HeLa epithelial cells were
treated with ciprofloxacin (2 ng/ml to 1 μg/ml), lamellar phase
liquid crystal emulsion (LP: 10 μl to 100 μl), LP encapsulated
ciprofloxacin (LPC: 10 μl to 100 μl ≡ 50 ng/ml to 500 ng/ml
of ciprofloxacin) or the control (TFA in deionised water at the
same final concentration as for LPC) for 24 h. Initially, treat-
ments were added directly onto cells. No observable effect
was noted following addition of ciprofloxacin to the cell cul-
ture (data not shown), but following the addition of liquid
crystal emulsions, a corona surrounding the liquid crystal,
which was devoid of cells was noted in both HEC1A (Fig.
4a) and HeLa (Fig. 4b) cell cultures. Because of interference
between the liquid crystal emulsions and the MTT
assay reagents, cell cytotoxicity experiments were
performed using Transwell™ support membranes with liq-
uid crystal emulsions held in the Transwell™ and cells in
the basal compartment of the plate. Treatment of HEC1A
cells with ciprofloxacin resulted in reduced cell counts
demonstrating a cytotoxic effect compared to treatment
with the control (Fig. 4c). The effect, however, was not
dose dependent and interestingly, was not observed in
HeLa cells treated with ciprofloxacin (Fig. 4d) or in either
HEC1A or HeLa cells once the ciprofloxacin was encapsu-
lated in lamellar phase liquid crystal (LPC, Fig. 4g and h,
respectively), suggesting that encapsulated ciprofloxacin is
non-toxic to human cells. Treatment of HEC1A (Fig. 4e) or
HeLa (Fig. 4f) cells with LP did not affect cell viability
compared to control treated cells.
3.4 Encapsulation of ciprofloxacin within a liquid
crystal emulsion significantly enhances bacterial
killing
Effective and appropriate models for the evaluation of novel
therapeutics are an essential tool for drug development. In
considering an appropriate model for infection of the female
reproductive tract we selected bovine endometrial tissue,
which is readily available to us and a suitable model of the
human female reproductive tract due to similarities of struc-
ture, function and response to bacterial infection (Sheldon
Fig. 1 Liquid crystal emulsions
were prepared in different phases
through controlled application of
water content and heat: a
Lamellar phase emulsions were
obtained by mixing Monomuls®
with a solution of 0.05% TFA
(95% to 5%, w/v), heating the
solution to 40 °C and then
maintaining at 37 °C; b Cubic
phase emulsions were obtained
by mixing Monomuls® with a
solution of 0.05% TFA (75% to
25%, w/v) and after heating to
40 °C, the solution was cooled to
ambient room temperature,
undergoing a phase shift to the
cubic structure in the process, and
stored at room temperature until
needed. Ciprofloxacin was
incorporated into the liquid
crystal structures by addition
whilst at 40 °C
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et al. 2017; Turner et al. 2012). A common bacterial infection
within the bovine female reproductive tract, E. coli is one of
the most prevalent bacterium associated with uterine disease
in cattle. (Sheldon et al. 2009). Thus, wemodelled infection of
the female reproductive tract using primary bovine endome-
trial epithelial cells and EVOCs of the bovine endometrium,
which have been previously used as effective models of infec-
tion, inflammation and for drug development (Borges et al.
2012; Healey et al. 2016; Saut et al. 2014).
Initial experiments investigated the effect of treatment on
bacterial growth alone (Fig. 5). E. coli (MS499) was diluted to
1 × 103 colony forming units (CFU)/ml in LB medium for
bactericidal experiments and treated with ciprofloxacin
(Cipro: 10 ng/ml to 1 μg/ml), lamellar phase liquid crystal
emulsion (LP: 10 μl to 100 μl) or LP encapsulated ciproflox-
acin (LPC: 10 μl to 100 μl ≡ 50 ng/ml to 500 ng/ml of cipro-
floxacin). Bacterial growth in the presence or absence of treat-
ments was monitored for 24 h (Fig. 5a), 48 h (Fig. 5b) or 72 h
(Fig. 5c), after which bacterial growth (number of CFU) was
Fig. 2 Scanning electron
microscope characterization of
cubic phase liquid crystal
formulations: samples were
deposited on a silicon surface,
snap frozen in liquid nitrogen to
maintain the conformational
stability of the liquid crystals and
then coated with a 2 nm carbon
layer. a–f images obtained at 60×,
110×, 350×, 799×, 800× and
2500× respectively, show a
crystalline structure typical to
cubic phase liquid crystal
formulations. Images were
acquired with an S-4800 scanning
electron microscope (Hitachi)
operated at accelerating voltages
of 2 or 10 kV
Fig. 3 Encapsulated ciprofloxacin displayed sustained release
characteristics from cubic phase liquid crystal structures: cubic phase
liquid crystal encapsulated ciprofloxacin was sealed in a semi-
permeable membrane and placed in a 0.05%TFA solution. Samples were
extracted at various time points over a 72-h period. Data shown is mean
(SD), n = 3. Area under curve (AUC) analysis was performed using
GraphPad PRISM 6
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determined. At all three time points, treatment with LP had no
effect on bacterial growth. Treatment with ciprofloxacin sig-
nificantly reduced bacterial growth at all time points with no
growth observed at ciprofloxacin concentrations above
350 ng/ml. A reduction in bacterial growth was also observed
following treatment with LPC, whichwas significantly greater
compared to ciprofloxacin treatment with no growth observed
at LPC volumes above 12 μl ≡ 60 ng/ml. To determine the
non-inhibitory concentration (NIC) and minimum inhibitory
concentration (MIC) for ciprofloxacin (Sup. Fig. 2) and LPC
(Sup. Fig. 3) treatments, data was also fitted to a Gompertz
model using the method described by Lambert et al (Lambert
and Pearson 2000). Table 1 shows the NICs and MICs for the
two treatments at 24, 48 and 72 h, demonstrating the enhanced
bactericidal effect (lower NIC and lower MIC) of treatment
with LPC compared to ciprofloxacin. These data suggested
that liquid crystals enhance the effectiveness of antibiotics in
the treatment of bacterial diseases.
Fig. 4 Liquid crystal emulsions
have a limited impact on
epithelial cell viability: white
arrows indicate a corona devoid
of cells surrounding the liquid
crystal in both cell lines; a, b
Phase-contrast images of the
interaction between cubic phase
liquid crystal emulsion and
HEC1A or HeLa epithelial cells.
A corona devoid of cells can be
seen around the liquid crystal, but
no cell death was observed; c–h
HEC1A or HeLa epithelial cells
were treated with ciprofloxacin
(Cipro: 2 ng/ml to 1 μg/ml; C-D),
lamellar phase liquid crystal
emulsion (LP) (10μl to 100μl; E-
F) or LP encapsulated
ciprofloxacin (LPC) (10 μl to
100 μl ≡ 50 ng/ml to 500 ng/ml of
ciprofloxacin; G-H) for 24 h.
Scale bars = 500 μm. Data were
analysed by ANOVA using
Dunnett’s pairwise multiple
comparison. Data are presented as
mean (SD), n = 4. * p < 0.05, **
p < 0.01 compared to TFA
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To explore whether reduced bacterial growth would also
translate to reduced inflammation, we infected bovine epithe-
lial cells, and EVOCs with E. coli (MS499) and monitored
inflammatory responses by measuring interleukin (IL)-6 pro-
duction, which is associated with epithelial driven innate im-
mune responses in the endometrium (Cronin et al. 2012;
Healey et al. 2016; Sheldon and Roberts 2010) and responsi-
ble for acute and chronic inflammation (Gabay 2006).
Epithelial cells or EVOCs, previously treated with ciproflox-
acin, LP or LPC for 4 h, were cultured in the presence of
control medium or medium containing E. coli (MS499) at a
concentration of 1 × 103 CFU/ml for 24 h (Fig. 6). Infection of
epithelial cells with E. coli (MS499) significantly increased
the secretion of IL-6 in primary epithelial cell cultures.
Treatment with LP (Fig. 6a) did not reduce IL-6 secretion.
Conversely, a significant reduction in IL-6 production was
noted following treatment with ciprofloxacin concentrations
above 200 ng/ml (Fig. 6b) and following treatment with LPC
at a volume of 100 μl ≡ 500 ng/ml (Fig. 6c).
As with epithelial cells, infection of EVOCs with E. coli
(MS499) significantly increased the secretion of IL-6 in pri-
mary epithelial cell cultures (Fig. 7). Treatment with LP (Fig.
7a) had no impact on IL-6 secretion and significant reduction
in IL-6 production was noted following treatment with cipro-
floxacin concentrations above 200 ng/ml (Fig. 7b). For
EVOCs treated with LPC, a trend suggesting reduced IL-6
secretion was noted compared to E. coli (MS499) infected
EVOCs that had not been treated with LPC (Fig. 7c).
4 Discussion
In humans, infections of the female reproductive tract are a
major socio-economic burden that is associated with signifi-
cant morbidity and mortality (Horne et al. 2008). Additionally,
Fig. 5 Liquid crystal encapsulation enhances the bacterial toxicity of
ciprofloxacin: cultures of E. coli (MS499) (at 1 × 103 CFU/ml) were
prepared in LB medium and treated with ciprofloxacin (Cipro: 10 ng/ml
to 1 μg/ml), lamellar phase liquid crystal emulsion (LP: 10 μl to 100 μl)
or LP encapsulated ciprofloxacin (LPC: 10 μl to 100 μl ≡ 50 ng/ml to
500 ng/ml of ciprofloxacin) for 24 h (a), 48 h (b) or 72 h (c). Data were
analysed by ANOVA using Dunnett’s pairwise multiple comparison.
Data are presented as mean (SD), n = 4. ** p < 0.01, *** p < 0.001
compared to LP
Table 1 Non-inhibitory concentration (NIC) and minimum inhibitory
concentration (MIC) of ciprofloxacin and LPC for the treatment of E.coli
MS499
NIC (ng/ml) MIC (ng/ml)
Cipro LPC Cipro LPC
24 h 48.96 17.48 97.58 31.26
48 h 52.03 16.59 156.0 36.34
72 h 15.6 19.59 125.1 33.48
Data was fitted to a Gompertz model using the method described by
Lambert et al
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an increasing prevalence of bacterial resistance over the past
two decades means that previously effective antibiotic treat-
ments are being abandoned except in cases where specific
sensitivity can be demonstrated through additional testing
(Allan-Blitz et al. 2016; Conly and Johnston 2005; So and
Shah 2014). There is therefore an urgent need for novel ap-
proaches to the treatment of bacterial infections of the female
reproductive tract.
Establishing new localised drug delivery vehicles could
provide several benefits over conventional therapies that are
crucial to microorganism eradication related to bacterial infec-
tions. Improved pharmacokinetic and pharmacodynamic pro-
files reduce the amount of administered drug needed, com-
pared to systemic delivery, to obtain a clinically relevant ef-
fect. Improved half-lives and sustained, localised release at
concentrations above the bacteria’s minimum inhibitory con-
centration, when protecting against infection, or above the
minimum bactericidal concentration, when treating current
infection reduce the incidence of antibiotic resistance (Wu
and Grainger 2006). Improved drug efficacy and a reduced
need for repeated administrations also reduces costs and en-
hances patient compliance. Controlled-release platforms such
as liquid crystals offer great potential due to their inherent
structural characteristics that are ideally suited for encapsula-
tion of antibiotics such as ciprofloxacin. Moreover, the liquid
crystal platform presented here affords a slow-release profile,
allowing for prolonged treatments avoiding multiple dosing
regimens. Furthermore, the platform is minimally invasive
and can be applied locally, removing the need for oral or
intravenous administration.
Characterization of the liquid crystal formulations demon-
strated that they were not toxic to cervical (HeLa) or endome-
trial (HEC1A) epithelial cells, corroborating previous works
(Aldred et al. 2014; Card et al. 2015; Mason et al. 1995).
Some cell toxicity was noted in HEC1A cells following treat-
ment with ciprofloxacin, however the effect was not dose
dependent suggesting the observed effect might be of limited
biological significance. A variety of toxicities associated with
ciprofloxacin therapy are known (Amorha et al. 2018;
Oyebode et al. 2018; Stahlmann 1990; Stahlmann and Lode
2013) including arthropathogenic potential in animals, which
led to the decision to not use ciprofloxacin or other quinolones
in children or adolescents. Interestingly, cells treated with cip-
rofloxacin encapsulated within lamellar phase liquid crystal
Fig. 6 IL-6 secretion by E. coli (MS499) infected epithelial cells is
reduced following treatment with ciprofloxacin or liquid crystal encapsu-
lated ciprofloxacin: primary bovine epithelial cells were pre-treated with
control medium ormedium containing ciprofloxacin (Cipro: 100 ng/ml to
500 ng/ml), lamellar phase liquid crystal emulsion (LP: 20 μl to 100 μl)
or ciprofloxacin encapsulated liquid crystal emulsion (LPC: 20 μl to
100 μl ≡ 100 ng/ml to 500 ng/ml of ciprofloxacin) for 4 h. Cells were
subsequently challenged with control medium or medium containing 1 ×
103 CFU/ml E. coli (MS499) for 24 h. After challenge, supernatants were
collected and stored at −20 °C prior to analysis for IL-6, by ELISA. Data
were analysed by ANOVA using Dunnett’s pairwise multiple
comparison. Data are presented as mean (SD), n = 4. * p < 0.05, **
p < 0.01
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did not display any toxicity, suggesting the notion that the use
of such formulations may be a useful strategy to reduce tox-
icities associated with current treatment regimen.
In addition to reduced toxicity, ciprofloxacin encapsulation
significantly enhanced bacterial cell killing. LPC treatment was
five timesmore effective at killingE. coli than free-ciprofloxacin
demonstrating the great potential of this formulation for enhanc-
ing the efficacy and sustained delivery of antibiotic agents.
Central to the response to bacterial challenge is the detection
of pathogen-associated molecular patterns by toll-like receptors
(Amjadi et al. 2014). Reproductive tract immune responses to
E. coli infection require the binding of lipopolysaccharide from
E. coli to toll-like receptor 4 on the surface of epithelial cells,
which then produce IL-6 (Herath et al. 2006; Sheldon and
Roberts 2010). The kinetics of IL-6 production reflecting its roles
in the early response to infection such as leukocyte recruitment,
B lymphocyte development, antibody secretion by plasma cells
and the regulation of acute-phase proteins.
Interleukin-6 rapidly accumulates during the first 24 h fol-
lowing exposure to E. coli (Sheldon and Roberts 2010), and
was attenuated by treatment with free- and encapsulated
(LPC) ciprofloxacin. As expected, attenuation was more pro-
nounced in epithelial cells than EVOCs. The purified cell
model does not support inflammasome activation and IL1β
secretion, which leads to the production of additional pro-
inflammatory cytokines, such as more IL-6 (van de
Fig. 7 IL-6 secretion by E. coli (MS499) infected EVOCs is reduced
following treatment with ciprofloxacin or liquid crystal encapsulated
ciprofloxacin: EVOCs were pre-treated with control medium or medium
containing ciprofloxacin (Cipro: 100 ng/ml to 500 ng/ml), lamellar phase
liquid crystal emulsion (LP: 20 μl to 100 μl) or ciprofloxacin
encapsulated liquid crystal emulsion (LPC: 20 μl to 100 μl ≡ 100 ng/ml
to 500 ng/ml of ciprofloxacin) for 4 h. EVOCs were subsequently
challenged with control medium or medium containing 1 × 103 CFU/ml
E. coli (MS499) for 24 h. After challenge, supernatants were collected
and stored at −20 °C prior to analysis of IL-6, by ELISA. EVOC tissues
were weighed to enable cytokine concentrations to be adjusted for tissue
weight. Data were analysed by ANOVA using Dunnett’s pairwise
multiple comparison. Data are presented as mean (SD), n = 4. ** p < 0.01
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Veerdonk et al. 2011), and chemokines such as IL-8 that re-
cruit cells and promote phagocytosis and bacterial clearance
(Pétrilli et al. 2007). Although treatment with free-
ciprofloxacin appeared more efficacious than treatment with
LPC, this is likely due to the concentration of ciprofloxacin
present in the culture medium during this 24 h experiment.
Whilst the full dose is immediately available following treat-
ment with free-ciprofloxacin, the antibiotic is released slowly
over the course of the experiment with LPC. Such a release
profile will likely have significant advantages during longer-
term infection, whereby the sustained presence of antibiotic
will reduce IL-6 production and reduce bacterial load more
effectively than the free drug. An expected effect corroborated
by the application of liquid crystals for the slow release of
drugs with a wide range of molecular weights and water sol-
ubilities (Esposito et al. 1996; Geraghty et al. 1996; Nesseem
2001; Nguyen et al. 2011; Nguyen TH et al. 2010; Omray
2013; Wyatt and Dorschel 1992). Myriad factors influence
the dynamics of drug release from liquid crystal delivery plat-
forms including temperature, pressure, pH, the molecular
weight of the drug, hydrophobicity and salt concentration.
Optimization based on the clinical application environment
is therefore an important consideration of the drug formulation
design process to ensure optimal efficacy.
These data demonstrate that the liquid crystal controlled-
release platform presented is effective at delivering antibiotics
to treat bacterial infections within the female reproductive tract.
Such a platform has potential clinical application supporting a
drive towards localised delivery of antibiotic therapies over
systemic delivery. Liquid crystal systems have been extensively
employed in the clinic as anticancer, anti-inflammatory, analge-
sic and immunosuppressive agents, amongst others (Chaudhary
et al. 2016; Kim et al. 2015; Mei et al. 2018). Indeed, we
envisage such a platform being used for topical delivery by
the patient for the treatment of lower reproductive tract infec-
tions, and/or topical administration by amedical practitioner for
upper reproductive tract infections. As well as addressing an
important unmet need for efficacious therapies that can reduce
negative side effects associated with systemic exposure and
offer significant health and economic benefits. Such an ap-
proach also provides the potential to increase the efficacy and
extend the effective therapeutic life-span of existing antibiotics
by reducing the rate of emergence of antibiotic resistance.
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